Report overview
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
This report contains market size and forecasts of Neuroblastoma Treatment Drugs in global, including the following market information:
Global Neuroblastoma Treatment Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Neuroblastoma Treatment Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Neuroblastoma Treatment Drugs companies in 2021 (%)
The global Neuroblastoma Treatment Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cyclophosphamide Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neuroblastoma Treatment Drugs include United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Neuroblastoma Treatment Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neuroblastoma Treatment Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neuroblastoma Treatment Drugs Market Segment Percentages, by Type, 2021 (%)
Cyclophosphamide
Dinutuximab
Naxitamab
Doxorubicin Hydrochloride
Vincristine Sulfate
Other
Global Neuroblastoma Treatment Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neuroblastoma Treatment Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Other
Global Neuroblastoma Treatment Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neuroblastoma Treatment Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neuroblastoma Treatment Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Neuroblastoma Treatment Drugs revenues share in global market, 2021 (%)
Key companies Neuroblastoma Treatment Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Neuroblastoma Treatment Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
United Therapeutics
Y-mAbs Therapeutics
EUSA Pharma
ANI Pharmaceuticals
Baxter Healthcare
Ingenus Pharmaceuticals
Pfizer
Hikma Pharmaceuticals
Teva Pharmaceuticals
